169 related articles for article (PubMed ID: 3149842)
1. [Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients].
Stoliarova LG; Kadykov AS; Shvedkov VV; Shakhparonova NV
Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):11-3. PubMed ID: 3149842
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
3. MAO-B inhibitor know-how: back to the pharm.
Lewitt PA
Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
[No Abstract] [Full Text] [Related]
4. [Use of iumeks in the combined therapy of parkinsonism patients ].
Man'kovskiĭ NB; Karaban' IN; Mialovitskaia EA
Vrach Delo; 1987 Aug; (8):100-2. PubMed ID: 3120415
[No Abstract] [Full Text] [Related]
5. Transdermal selegiline (Emsam).
Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
[No Abstract] [Full Text] [Related]
6. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
8. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
9. Selegiline for Parkinson's disease.
Calesnick B
Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
[TBL] [Abstract][Full Text] [Related]
10. Selegiline in Parkinson's disease.
Calne DB
BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
[No Abstract] [Full Text] [Related]
11. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
Bainbridge JL; Page RL; Ruscin JM
Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy of the Umex treatment of parkinsonism patients in the initial stage of the disease].
Fedorova NV; Glozman ZhM; Saltykova NM
Ter Arkh; 1995; 67(10):75-7. PubMed ID: 8779116
[TBL] [Abstract][Full Text] [Related]
13. Selegiline HC1: Selective MAO-type B inhibitor.
Koller WC; Giron LT
Neurology; 1990 Oct; 40(10 Suppl 3):suppl 58-60. PubMed ID: 2120616
[No Abstract] [Full Text] [Related]
14. [Drug therapy of Parkinson's disease].
Myllylä V
Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
[No Abstract] [Full Text] [Related]
15. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Parkinson's disease.
Eadie MJ
Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
[TBL] [Abstract][Full Text] [Related]
17. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
LeWitt PA
Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310
[No Abstract] [Full Text] [Related]
18. Monoamine oxidase inhibitors--is it time to up the TEMPO?
Rascol O
Lancet Neurol; 2003 Mar; 2(3):142-3. PubMed ID: 12849233
[No Abstract] [Full Text] [Related]
19. Selegiline, pregnancy, and Parkinson's disease.
Kupsch A; Oertel WH
Mov Disord; 1998 Jan; 13(1):175-6. PubMed ID: 9452347
[No Abstract] [Full Text] [Related]
20. Parkinson's disease: drug therapy.
Oertel WH; Quinn NP
Baillieres Clin Neurol; 1997 Apr; 6(1):89-108. PubMed ID: 9426870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]